Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEM NASDAQ:CLLS NYSE:MBX NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$7.53-3.1%$8.02$6.85▼$21.01$458.54M-0.08497,182 shs221,414 shsCLLSCellectis$1.82-5.7%$1.53$1.10▼$2.43$107.28M2.91150,425 shs133,053 shsMBXMBX Biosciences$11.75-3.6%$11.80$4.81▼$27.50$392.73MN/A264,355 shs273,419 shsRZLTRezolute$5.39-2.7%$4.37$2.22▼$6.19$473.78M1.03669,654 shs664,138 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics+1.30%-0.89%-6.61%-1.52%-58.02%CLLSCellectis-3.02%+16.97%+40.88%+33.10%-8.53%MBXMBX Biosciences-1.93%-1.69%+20.69%+59.97%+1,218,999,900.00%RZLTRezolute+3.55%+5.52%+34.14%+101.45%+19.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGEMCullinan Therapeutics1.7363 of 5 stars3.50.00.00.02.21.70.6CLLSCellectis3.4276 of 5 stars3.54.00.00.03.32.50.6MBXMBX Biosciences2.341 of 5 stars3.50.00.00.02.41.70.6RZLTRezolute2.4345 of 5 stars3.61.00.00.02.04.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 3.00Buy$30.00298.41% UpsideCLLSCellectis 3.00Buy$4.00119.78% UpsideMBXMBX Biosciences 3.00Buy$37.57219.76% UpsideRZLTRezolute 3.14Buy$11.83119.54% UpsideCurrent Analyst Ratings BreakdownLatest CLLS, CGEM, MBX, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.006/11/2025CGEMCullinan TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$22.005/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.005/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/ACLLSCellectis$49.22M2.06N/AN/A$2.36 per share0.77MBXMBX BiosciencesN/AN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/6/2025 (Estimated)CLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)MBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/ARZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)Latest CLLS, CGEM, MBX, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CGEMCullinan Therapeutics-$0.7951N/AN/AN/AN/AN/A8/5/2025N/ACLLSCellectis-$0.15N/AN/AN/A$10.07 millionN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A11.6211.62CLLSCellectis0.441.671.67MBXMBX BiosciencesN/AN/AN/ARZLTRezoluteN/A8.438.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%CLLSCellectis63.90%MBXMBX BiosciencesN/ARZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics7.16%CLLSCellectis16.41%MBXMBX Biosciences52.19%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3059.01 million54.79 millionOptionableCLLSCellectis29055.58 million46.46 millionOptionableMBXMBX Biosciences3633.42 millionN/AN/ARZLTRezolute4085.52 million69.79 millionOptionableCLLS, CGEM, MBX, and RZLT HeadlinesRecent News About These CompaniesRezolute Completes Enrollment for Phase 3 sunRIZE StudyJuly 18 at 6:52 AM | tipranks.comRezolute files to sell 1.3M shares of common stock for holdersJuly 18 at 5:52 AM | msn.comBrokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $11.83July 12, 2025 | americanbankingnews.comRezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of ...July 10, 2025 | finance.yahoo.comRezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)July 9, 2025 | globenewswire.comRezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Buy" from AnalystsJuly 9, 2025 | marketbeat.comBrian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockJune 27, 2025 | insidertrades.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) Insider Buys 2,500 Shares of StockJune 26, 2025 | marketbeat.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of StockJune 25, 2025 | insidertrades.comRezolute, Inc. (NASDAQ:RZLT) CFO Acquires $20,250.00 in StockJune 24, 2025 | marketbeat.comYoung-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockJune 24, 2025 | insidertrades.comYoung-Jin Kim Acquires 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockJune 23, 2025 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%June 3, 2025 | finance.yahoo.comRezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital HyperinsulinismMay 28, 2025 | globenewswire.comRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 21, 2025 | finanznachrichten.deRezolute, Inc. (RZLT): Analysts See 260% Upside PotentialMay 20, 2025 | finance.yahoo.comRezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia TreatmentMay 15, 2025 | nasdaq.comRezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comFDA grants breakthrough status to Rezolute’s hypoglycemia therapyMay 6, 2025 | investing.comRezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor HyperinsulinismMay 5, 2025 | globenewswire.comRezolute to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS, CGEM, MBX, and RZLT Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$7.53 -0.24 (-3.09%) Closing price 04:00 PM EasternExtended Trading$7.52 0.00 (-0.07%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Cellectis NASDAQ:CLLS$1.82 -0.11 (-5.70%) Closing price 04:00 PM EasternExtended Trading$1.85 +0.03 (+1.65%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.MBX Biosciences NYSE:MBX$11.75 -0.44 (-3.61%) Closing price 04:00 PM EasternExtended Trading$11.73 -0.02 (-0.17%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Rezolute NASDAQ:RZLT$5.39 -0.15 (-2.71%) Closing price 04:00 PM EasternExtended Trading$5.50 +0.11 (+2.04%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
